Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
18 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
IRX Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'IRX Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the IRX Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of IRX Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of IRX Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of IRX Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the IRX Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate IRX Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of IRX Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the IRX Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of IRX Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of IRX Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of IRX Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 IRX Therapeutics, Inc. Snapshot 4 IRX Therapeutics, Inc. Overview 4 Key Information 4 Key Facts 4 IRX Therapeutics, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 IRX Therapeutics, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 IRX Therapeutics, Inc. - Pipeline Products Glance 9 IRX Therapeutics, Inc. - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 IRX Therapeutics, Inc. - Drug Profiles 10 IRX-3 10 Product Description 10 Mechanism of Action 10 R&D Progress 10 IRX-46 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 Methyl Inosine Monophosphate 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 IRX Therapeutics, Inc. - Pipeline Products by Route of Administration 13 IRX Therapeutics, Inc. - Pipeline Products by Molecule Type 14 IRX Therapeutics, Inc. - Dormant Projects 15 IRX Therapeutics, Inc. - Locations And Subsidiaries 16 Head Office 16 Appendix 17 Methodology 17 Coverage 17 Secondary Research 17 Primary Research 17 Expert Panel Validation 17 Contact Us 18 Disclaimer 18
List of Tables IRX Therapeutics, Inc., Key Information 4 IRX Therapeutics, Inc., Key Facts 4 IRX Therapeutics, Inc. - Pipeline by Indication, 2014 6 IRX Therapeutics, Inc. - Pipeline by Stage of Development, 2014 7 IRX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8 IRX Therapeutics, Inc. - Preclinical, 2014 9 IRX Therapeutics, Inc. - Pipeline by Route of Administration, 2014 13 IRX Therapeutics, Inc. - Pipeline by Molecule Type, 2014 14 IRX Therapeutics, Inc. - Dormant Developmental Projects,2014 15
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.